Our top pick for
Biogen Inc is a drug manufacturers—general business based in the US. Biogen shares (BIIB) are listed on the NASDAQ and all prices are listed in US Dollars. Biogen employs 7,400 staff and has a trailing 12-month revenue of around USD$14.5 billion.
|52-week range||USD$219.7 - USD$374.99|
|50-day moving average||USD$280.0606|
|200-day moving average||USD$290.3916|
|Wall St. target price||USD$305.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$34.044|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Biogen shares trade at around 8x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$8 billion.
The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$14.5 billion|
|Operating margin TTM||52.37%|
|Gross profit TTM||USD$12.4 billion|
|Return on assets TTM||18.31%|
|Return on equity TTM||49.38%|
|Market capitalisation||USD$42.5 billion|
TTM: trailing 12 months
There are currently 3.3 million Biogen shares held short by investors – that's known as Biogen's "short interest". This figure is 39.1% up from 2.4 million last month.
There are a few different ways that this level of interest in shorting Biogen shares can be evaluated.
Biogen's "short interest ratio" (SIR) is the quantity of Biogen shares currently shorted divided by the average quantity of Biogen shares traded daily (recently around 1.3 million). Biogen's SIR currently stands at 2.63. In other words for every 100,000 Biogen shares traded daily on the market, roughly 2630 shares are currently held short.
However Biogen's short interest can also be evaluated against the total number of Biogen shares, or, against the total number of tradable Biogen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biogen's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Biogen shares in existence, roughly 20 shares are currently held short) or 0.021% of the tradable shares (for every 100,000 tradable Biogen shares, roughly 21 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biogen.
Find out more about how you can short Biogen stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Biogen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 23.93
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Biogen's overall score of 23.93 (as at 08/01/2020) is pretty good – landing it in it in the 33rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Biogen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.02/100
Biogen's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13.48/100
Biogen's social score of 13.48 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 8.43/100
Biogen's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Biogen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Biogen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Biogen has, for the most part, managed to keep its nose clean.
|Total ESG score||23.93|
|Total ESG percentile||33.4|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||2|
We're not expecting Biogen to pay a dividend over the next 12 months.
Biogen's shares were split on a 3:1 basis on 18 January 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.
Over the last 12 months, Biogen's shares have ranged in value from as little as $219.7 up to $374.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is 0.5234. This would suggest that Biogen's shares are less volatile than average (for this exchange).
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.